CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial Discharge Against Medical Advice After Percutaneous Coronary Intervention in the United States Large-Bore Radial Access for Complex PCI: A Flash of COLOR With Some Shades of Grey Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization Best Practices for the Prevention of Radial Artery Occlusion After Transradial Diagnostic Angiography and Intervention An International Consensus Paper Randomized Comparison Between Radial and Femoral Large-Bore Access for Complex Percutaneous Coronary Intervention

Original Research2018 Jun;25(3):769-776.

JOURNAL:J Nucl Cardiol. Article Link

Guidelines in review: Comparison of the 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes and the 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Prejean SP, Din M, Reyes E et al. Keywords: Non-ST elevation acute coronary syndrome; coronary artery disease; non-invasive imaging; stress testing

ABSTRACT


In this Guidelines in Review, we review side-by-side the recommendations provided by the 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes and the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. We review the recommendations for imaging in the evaluation of patients with possible ACS followed by the diagnostic evaluation of patients with proven NSTE-ACS, based on their risk for adverse clinical events.